SCHEMBL21595372

SCHEMBL21595372

C=CCC1CC2(CCCN2C(=O)OC(C)(C)C)CC1=O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39
JAK3 P52333 2/20 0.36
KDM1A O60341 2/20 0.35
SPR P35270 3/20 0.33
CNR2 P34972 2/20 0.33
CNR1 P21554 1/20 0.33
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
NAMPT P43490 4/20 0.32
FAAH O00519 1/20 0.32
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31
PDE4A P27815 1/20 0.30
PDE4B Q07343 1/20 0.30
PDE4C Q08493 1/20 0.30
PDE4D Q08499 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21595437 0.82 FAAH (0.37) FAAH
SCHEMBL21595419 0.78 GRIN2B (0.35) GRIN2BGRIN2CJAK3SPRCNR2
SCHEMBL21595458 0.78 ELANE (0.45)
SCHEMBL21274551 0.75 GRIN2B (0.45) GRIN2BGRIN2CJAK3SPRCNR2
SCHEMBL21595331 0.74 DDB1 (0.37) DDB1CRBNFAAHKDM4EMAPT
SCHEMBL31293350 0.73 FAAH (0.42) DDB1CRBNFAAHMAPTPDE4A
SCHEMBL626378 0.73 FAAH (0.43) KDM1ADDB1CRBNFAAHKDM4E
SCHEMBL14669188 0.72 JAK3 (0.45) GRIN2BGRIN2CJAK3SPRCNR2
SCHEMBL21274184 0.72 GRIN2B (0.43) GRIN2BGRIN2CJAK3KDM1ASPR
SCHEMBL26916200 0.71 GRIN2B (0.43) GRIN2BGRIN2CJAK3SPRCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3810615-B1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2026-01-28 EP disclosed
US-11274111-B2 Arginase inhibitors and methods of use MERCK SHARP & DOHME CORP. (US) 2022-03-15 US disclosed
US-20210163505-A1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2021-06-03 US disclosed
US-20210163505-A1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2021-06-03 US disclosed
EP-3810615-A1 ARGINASE INHIBITORS AND METHODS OF USE Merck Sharp & Dohme Corp. (US) 2021-04-28 EP disclosed
WO-2019245890-A1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163505-A1 ARGINASE INHIBITORS AND METHODS OF USE ARG1, ARG2, PRMT1 GRIN2B 1608/4885GRIN2C 2482/4885JAK3 3710/4885
US-11274111-B2 Arginase inhibitors and methods of use ARG1, ARG2, PRMT1 GRIN2B 1608/4885GRIN2C 2482/4885JAK3 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.